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Background: Multiple myeloma is a hematologic malignancy characterized by the accumulation of monoclonal
plasma cells in the bone marrow. A common manifestation of the disease is myeloma bone disease (MBD), which is
caused by increased osteoclastic bone resorption and decreased bone formation. The chemokine cytokine ligand 3
(CCL3) is a pro-inflammatory protein and chemokine that stimulates osteoclasts in MBD. However, little is known
about the effect of CCL3 on osteoblasts (OB).
Methods: The OBs are induced from patients with MBD and healthy donors, cultured in vitro, and identified by
histochemistry. The effects of CCL3 and CCL3 antibody on the OBs in vitro are observed. The CCL3 receptor (CCR1),
osteocalcin (OCN), runt-related transcription factor 2 (Runx2), and osterix (Osx) are detected using flow cytometry,
enzyme-linked immunosorbent assay, and real-time PCR.
Results: Proliferation and osteogenic potential of the OB in patients with MBD are suppressed. Moreover, the CCR1
expression is significantly higher in patients with MBD than in normal controls. The OCN level, quantity of calcium
nodules, and Runx2 and Osx levels decrease after CCL3 stimulation, which indicates that CCL3 inhibits OB function.
Furthermore, CCL3 antibody partially restores OB activity through the upregulation of the OCN, Runx2, and Osx.
Conclusions: CCL3 contributes to the OB/OC imbalance by inhibiting OB differentiation and function in MBD.
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Majority of patients with multiple myeloma (MM) suffer
from bone osteolytic lesions also called myeloma bone
disease (MBD). MBD may lead to severe complications
including pain and fracture. The formation of new
bones, which normally occurs in sites of previous bone
destruction, is absent or markedly suppressed [1]. Con-
sequently, the osteolytic lesions rarely heal because of
the MM-induced suppression of osteoblast (OB) activity
even when the patients have prolonged remission and
the MM cells are not detectable. The mechanism of OB
suppression remains unclear until now.
The bone marrow stromal cells, OBs, osteoclasts
(OC), endothelial cells and immune cells in a normal
condition regulate each other’s function through direct* Correspondence: florai@sina.com; shaozonghong@sina.com
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unless otherwise stated.cell-to-cell contact, cytokine secretion, or extracellular
matrix protein deposition. Uncoupled bone remodeling
results from the imbalanced activity of OCs and OBs in
patients with MM. The chemokine cytokine ligand 3
(CCL3), which is also known as the macrophage inflam-
matory protein 1-alpha (MIP-1α), is one of the factors
responsible for decreased bone formation. CCL3 is a low
molecular weight monokine with inflammatory and
chemokinetic properties characterized as an osteoclast
stimulatory factor in MM [2,3]. CCL3 is elevated in the
bone marrow plasma cells of patients with active MM
and correlated with the presence of osteolytic lesions [2].
Serum MIP-1α correlates with survival and bone resorp-
tion markers, which suggests that MIP-1α possibly
contributes to MBD pathogenesis and tumor growth as
reflected by its effect on survival [4,5]. MIP-1α also stim-
ulates proliferation, migration, and survival of plasma
cells [6,7]. hMIP-1α receptors (i.e., CCR1 and CCR5) are
expressed in human bone marrow cells [8]. However, noThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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OB. Thus, this study investigates the effect of CCL3 on
the OB of patients with MBD.
Methods
Study subjects
A total of 21 newly diagnosed patients with MBD (i.e., 13
males and 8 females) were enrolled. The participants
were selected as inpatients in the Hematology Department
of the General Hospital of the Tianjin Medical University
between January and December 2013 according to the
International Myeloma Workgroup criteria. The patient
median age was 61 years old (range: 44–74 years). Eight
healthy volunteers with a median age of 40.5 years old
(range: 19–65 years) were included as normal controls.
Bone marrow aspirations were collected from all the pa-
tients diagnosed with MBD and from normal controls.
This study was approved by the Ethics Committee of the
Tianjin Medical University. Written informed consent was
obtained from the patient for the publication of this report
and any accompanying images.
Cell culture
The bone marrow mononuclear cells (BMMNC) were
separated using Ficoll–Hypaque density sedimentation.
The BMMNCs were cultured in Dulbecco’s modified
Eagle/F12 medium supplemented with 15% fetal bovine
serum (Gibco, Darmstadt, Germany), 1 × 10−7 mol/L
dexamethasone, 0.05 g/L vitamin C, 0.01 mol/L β-
sodium glycerophosphate, 100 U/mL penicillin (Gibco),
and 100 ug/mL streptomycin (Gibco). Non-adherent
cells were removed the next day, and the media were re-
placed every other day. Adherent BMMNCs were cultured
at 37°C in an atmosphere containing 5% CO2. The OBs
were counted and seeded in 24-well plates at a plating
density of 1 × 104 cells/cm2. Trypsin was used to detach
three wells of OB for cell count every second day. The
number of cells was used to draw the OB growth curve.
The OB doubling time (DT) was calculated using the
following formula:
DT ¼ t  1g2= 1gNt−1gNoð Þ½ 
where t is the culturing period (h); No is the cell dens-
ity when the cells were seeded; and Nt is the cell density
when the cells were cultured after t hours.
The OBs were divided into three groups: group I
(i.e., blank group), group II (i.e., the OBs were cul-
tured with CCL3; 50 ng/L), and group III [i.e., the
OBs were cultured with CCL3; 50 ng/L; and a neu-
tralizing antibody against CCL3 (R&D Systems) with
5 μg/L concentration]. The changes in the OB osteo-
genic potential and biological characteristics were observed
after intervention.ALP activity and mineralization assays
The ALP expression was an early osteoblast marker
detected using the ALP Staining Kit (Sigma Aldrich,
Taufkirchen, Germany). The expression was utilized to
confirm the presence of OB. Von Kossa staining was
performed to confirm that the OB synthesized and min-
eralized an extracellular matrix. The mineralized nodules
were found in both groups cultured for three weeks. The
amount of mineralized nodules in each patient was
counted and used as an indicator of OB function.
Flow cytometry
The OBs were suspended in Dulbecco’s phosphate-
buffered saline (PBS) and incubated with antibodies
against mouse IgG1-PE,mouse IgG1-APC, mouse IgG1-
FITC and mouse IgG1-PerCP (BD, Franklin Lakes, NJ,
USA) as a negative control. Antibodies against CCR1-PE,
CD138-FITC,CD45-APC and CD34-PerCP (BD) were used
to stain the experimental sample. After incubation in the
dark at 4°C for 30 min,the cells were washed twice with
PBS. At least 5 × 104 cells were acquired and analyzed
using a FACSCalibur flow cytometer (BD Biosciences).
OBs are marked as CD138−CD45−CD34− cells.
Enzyme-linked immunosorbent assay
The OBs were cultured for 3 days, and the supernatants
were harvested. The OB-secreted osteocalcin (OCN) level
in the supernatants was assessed using the N-MID OCN
ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA).
Diluted standards and patient serum (100 μl) were added
in duplicate and incubated at 37°C for 1 h. Then, the wells
were washed 5 times using a microplate washer. Next,
HRP was added to each well. After incubation at 37°C for
30 min, the wells were washed 5 times. Then, TMB solu-
tion was added to each well, and the samples were incu-
bated in the dark at room temperature for 20 min. Finally,
a stop solution was added, and the OD was read at
450 nm within 15 min.
Quantitative real-time PCR
The total RNA from the OB of each group was extracted
using the TRIzol reagent (Invitrogen). The TIANScript
RT Kit (TIANGEN, Beijing, China) was utilized to reverse-
transcribe 1 μg of RNA. Table 1 presents the primer
sequences. These primer sequences were designed and
synthesized by Sangon Biotech (Shanghai, China).
The quantitative real-time PCR was performed using
the Bio-Rad iQ 5 Real-time System (Bio-Rad, Hercules,
CA, USA). The SYBR Green (Invitrogen) was used as a
double-strand DNA-specific dye. The amplification uti-
lized 40 cycles at 95°C for 10 s and 58°C for 20 s with the
extension at 72°C for 30 s. β-Actin was employed as the
housekeeping gene to standardize the targeted mRNA
expression. The runt-related transcription factor 2 (Runx2),
Table 1 Primer sequences
Target Sense and anti-sense sequences Bp
Runx2 F: 5′-AACCACAGAACCACAAGTGCG-3′ 119 bp
R: 5′-AAATGACTCGGTTGGTCTCGG-3′
Wnt3a F: 5′-GCCCCCACTCGGATACTTCTTACTC-3′ 226 bp
R: 5′-CTCCTGGATGCCAATCTTGATG-3′
Osterix (SP17) F: 5′-CTGCGGGACTCAACAACTCT-3′ 194 bp
R: 5′-TGGGAAAAGGGAGGGTAATC-3′
β-Actin F: 5′-TTGCCGACAGGATGCAGAA-3′ 100 bp
R: 5′-GCCGATCCACACGGAGTACT-3′
Bp: base pairs.
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the 2−△△Ct method [(Ct, target gene Ct, β-actin)sample −
(Ct, target gene Ct, β-actin)control] after normalizing the
data according to the β-actin mRNA expression.
Statistical analysis
All data were expressed as mean and standard deviation.
The SPSS 16.0 software was used to perform all statis-
tical analyses. The differences between the means of the
data were calculated using Student’s t-test. The differ-
ences among the groups were analyzed by employing theFigure 1 Morphology of OBs. (A) The shape of the primary cells nearly r
reach confluency by day 7 and exhibit dense clusters at day 10. (C) OB mo
to 7 days and form continuous cell multilayers. The latter cultures form iso
dispersed on the flask surface. (D) The OB growth curve illustrates that the
constitutively suppressed.one-way analysis of variance followed by Newman–Keuls
multiple comparison test. P <0.05 was considered statisti-
cally significant.
Results
Decrease of proliferation and osteogenic potential of OB
from MBD
The OBs from the BM of patients with MBD were cul-
tured in vitro using dexamethasone, β-sodium glycero-
phosphate, and vitamin C. The shape of the cells nearly
resembles that of a spindle and a polygon (Figures 1A–C).
The OB growth curve showed that the proliferative
rate of the OB from the patients with MBD was con-
stitutively suppressed (Figure 1D). ALP and Von Kossa
staining positively identified the OB. The number of
positive cells and the amount of mineralized bone-like
nodules of the patients with MBD were less than those
of the normal controls (Figure 2). The DT was about
22 and 20 h in patients with MBD and normal con-
trols, respectively. Moreover, fewer cells were observed
from patients with MBD [(9.1 ± 3.28) × 104/mL] com-
pared with the normal controls [(11.2 ± 2.73) × 104/mL]
(P <0.05) 4 days after subculture. The proliferative rate
of the OB from patients with MM was constitutively
suppressed.esembles that of a spindle and a polygon. (B) The primary cultures
rphology after subculture. All subcultures reach confluency after 4 days
lated or interconnected and multilayered islands of cells widely
proliferative rate of the OB from patients with MBD are
Figure 2 OBs are identified through (A, B; C, D) ALP and Von Kossa staining. The number of positive cells of (B) the patients with MBD
is less than that of (A) the normal controls. The mineralized bone-like nodules in (D) the patients with MBD are less than those of (C) the
normal controls.
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The CCL3 receptor expression (i.e., CCR1) was detected
on both OB derived from the patients with MBD and
normal controls. The CCR1 expression on OB prompted
us to evaluate the effect of CCL3 on the development
and activity of OB. The CCR1 level on the OB was sig-
nificantly higher in patients with MBD (74.48 ± 7.31%)
than in the normal controls (48.35 ± 8.81%) (P <0.05)
(Figure 3). CCL3 played an important role in regulating
the OB of patients with MBD.
CCL3 inhibition of OB function through impaired
mineralization and downregulation of the OCN level
The OBs were cultured with or without CCL3 (50 ng/L)
for 6 days in vitro. The OB quantity and function
were subsequently observed. Matrix formation and
mineralization were also observed through histochemis-
try. The OCN level in the supernatants was detected by
ELISA. No change in the OB quantity was found with or
without CCL3, whereas the OB function was inhibited
with CCL3. The OB quantity co-cultured with CCL3 for
6 days was (2.42 ± 0.22) × 105/mL. This value was not dif-
ferent with that of the blank group (2.82 ± 0.19) × 105/mL
(Table 2). The OCN level cultured with CCL3 for 6 days
was (750.643 ± 41.116) μg/L, which was significantly lower
than that in the blank group [(803.375 ± 40.654) μg/L]
(P <0.05) (Figure 4). The amount of mineralized nodules
(5.42 ± 0.39/HPF) cultured with CCL3 was also signifi-
cantly lower than in the blank group (9.35 ± 0.62/HPF)
(P <0.05) (Table 2).Runx2 and Osx downregulation in OB of patients with MBD
The mRNA expressions of Runx2, Wnt, and Osx were
analyzed to observe OB differentiation. These expressions
were critical transcription factors for early and late OB dif-
ferentiation [9]. The mRNA in the blank group after CCL3
exposure in culture was 1.00, whereas that of Runx2,
Wnt, and Osx were 0.4002 ± 0.3734, 0.7341 ± 0.4432,
and 0.5242 ± 0.2809, respectively. The Runx2 and Osx
expressions were significantly lower than those in the blank
group (P <0.01). No difference was found in the Wnt
expression (Table 3).
Partial restoration of OB function by CCL3 antibody
The effect of the anti-CCL3 was observed on the OB
in vitro. The OCN level (787.358 ± 32.063 μg/L) and the
amount of mineralized nodules (6.88 ± 1.75/HPF) were
higher than those in the CCL3 group. However, no statis-
tical significance was found (Table 2). The mRNA expres-
sions of Runx2 and Osx after the anti-CCL3 antibody was
added were 0.8670 ± 0.6827 and 0.7993 ± 0.2468, respect-
ively. These expressions were significantly higher than
those of the CCL3 group (P <0.05). By contrast, the Wnt
mRNA expression had no significant difference under the
same condition (Table 3). The anti-CCL3 antibody partly
restored the OB differentiation by increasing the function
of the transcription factors.
Discussion
MM remained an incurable disease ultimately leading to
the death of all patients despite the significant progress
Figure 3 CCR1 expression is assessed using flow cytometry. The OB is marked as CD45−CD34−CD138−(A), which both express CCR1 in
(B) the patients with MBD and (C) normal controls. (D) The CCR1 level is significantly higher in patients with MBD (74.48 ± 7.31) % than in the
normal controls (48.35 ± 8.81) % (P <0.05).
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advances in the development of treatment strategies.
Osteolytic bone lesions still remained a therapeutic
challenge. The histomorphometric studies conducted
in the patients with MM with bone lesions showed
that bone remodeling was severely imbalanced becauseTable 2 Quantity and function of OB cultured with CCL3 and
Number of cases Number of cells (105/ml)
Blank 21 2.82 ± 0.19
CCL3 21 2.42 ± 0.22
Anti-CCL3 21 2.49 ± 1.23
*Significantly lower than that in the blank group. **Significantly lower than that in tthe increased bone resorption was not counterba-
lanced by the deposition of new bone tissues [10].
The OB activity was affected by a series of mecha-
nisms including the abnormal production of cytokines,
chemokines, and inflammatory factors, which usually in-
creased in the marrow microenvironment [11]. Abnormalanti-CCL3
Number of mineralized nodules (/HPF) OCN (μg/L)
9.35 ± 0.62 803.375 ± 40.654
5.42 ± 0.39* 750.643 ± 41.116**
6.88 ± 1.75 787.358 ± 32.063#
he blank group. #Significantly higher than that in the CCL3 group.
Figure 4 Effect of CCL3 on the OB of patients with MBD. (A) The OB morphology is not affected by CCL3. The OB of the blank group (A1) is
not different from the OB applied with the CCL3 treatment (A2). (B) The mineralized bone-like nodules of the OB in the CCL3 group (B2) are less
than that in the blank group (B1) (P <0.05). (C) The OCN level secreted by the OB is detected using ELISA. The secreted OCN reduces after stimulation
with CCL3 (P <0.05) and is partially restored by CCL3 antibody treatment (P <0.05). (D) Runx2 and Osx gene expressions in the OB assessed using
the quantitative PCR. The expressions are significantly downregulated with CCL3 treatment (P <0.01) but promoted after the CCL3 antibody is used
(P <0.05). The Wnt expression exhibits no change with or without the CCL3 antibody.
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cellular immunity in MM [12]. Moreover, deregulated
osteoblastogenesis was promoted by the direct OB
interactions with the myeloma cells. This interactionseverely suppressed both proliferation and differentiation
through the release of a number of inhibitory factors
such as Dickkopf-1 [13] and parathyroid hormone-related
protein [14].
Table 3 Gene expression in OB exposed to CCL3 and
anti-CCL3
Blank CCL3 Anti-CCL3
RUNX2 1.000 ± 0.0000 0.4002 ± 0.3734* 0.8670 ± 0.6827#
Wnt 1.000 ± 0.0000 0.7341 ± 0.4432 0.8246 ± 0.3579
Osterix 1.000 ± 0.0000 0.5242 ± 0.2809* 0.7993 ± 0.2468#
*Significantly lower than that in the blank group. #Significantly higher than
that in the CCL3 group.
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activity was not explained well because of the difficulty
of the human OB culture that limited the investigations.
We cultured MM-derived OBs in vitro and provided
a medium containing dexamethasone, vitamin C, and
β-sodium glycerophosphate. Dexamethasone regulated
gene expression in differentiating cells and induced the af-
finity of the glucocorticoid receptor for its target sequence
in the genome [15]. The bone cells were the target of the
glucocorticoid hormones. Vitamin C was required for the
synthesis of collagen [16] and osteogenesis in vitro
[17]. Anderson19 demonstrated that vitamin C regulated
ATPase and ATP activities and protein synthesis in cul-
tures of osteoblast-like cells. β-Sodium glycerophosphate
was often used in vitro to provide a potential source of
phosphate ions [18].
OB inhibition was frequent in the bone biopsies of pa-
tients with MM and was correlated with tumor burden
[19]. We have demonstrated that the OBs, which were
isolated from the BM in patients with MBD, showed a
decrease in quantity and mineralized activity compared
with the normal OBs of the healthy donors. The DT of
the MM-derived OBs was longer than that of the normal
controls. In agreement with the previous study [20],
these results suggested that the quantity and the prolif-
erative rate of the OBs from patients with MM were
constitutively suppressed.
Recent studies have further reported that CCL3 (MIP-
1α) was an osteoclastogenic C–C chemokine constitu-
tively secreted by most of the MM cells in patients with
multiple osteolytic lesions. The results of in vitro and
in vivo studies showed that CCL3 induced OC formation
in bone marrow cultures [21-23]. CCL3 acted as an OC-
stimulating factor in the human BM cultures and was
over-expressed in patients with MM but not in healthy
individuals [24]. We further showed that CCL3 contrib-
uted to the OB/OC imbalance by promoting OC activity
and by inhibiting OB activity.
In addition to OCs, OBs also expressed CCR1 recep-
tors. The MM-derived OBs expressed higher CCR1
levels than those in the normal controls. Accordingly,
CCL3 was involved in OB inhibition. We applied ELISA
to the OCN levels detected in the supernatant of the
MM-derived OBs exposed to CCL3 to verify whetherCCL3 inhibited OBs. The analysis showed that CCL3
downregulated the OCN expression,which is a late and
most cell-specific OB marker and also absent in endo-
chondral and membranous skeletal elements [25]. The
CCL3 exposure also impaired mineralization. The num-
ber of mineralized bone-like nodules of the OB in CCL3
was less than that of the blank controls, which suggested
that the OB function was inhibited after CCL3 treat-
ment. Vallet et al. [26] showed that mature OB from
primary cells and human stromal cell line (i.e., HS27A)
expressed higher levels of CCR1 and CCR5 mRNA than
immature OB. They concluded that the receptor expres-
sion observed on the mature cells accounted for the
preferential inhibition of OB function rather than differ-
entiation. We analyzed the OCN concentration to assess
the OB function and the mRNA expression of both Runx2
and Osx and to evaluate the degree of OB differentiation.
The OB maturation from mesenchymal cells was primar-
ily regulated by Runx2 [27]. The downstream factor Osx
[28] played a role in the late OB differentiation by promot-
ing the transcription of downstream genes such as OCN,
osteopontin, and bone morphogenetic proteins [29]. The
gene expression analysis of Runx2 and Osx revealed a
downregulation in the CCL3-treated OBs, which supported
the important role of CCL3 in inhibiting OB differentiation
and maturation. However, the exposure to CCL3 did not
significantly alter the expression levels of Wnt. We ac-
knowledged that canonical Wnt signaling governed the
lineage commitment and differentiation of progenitor cells
into chondrocytes and osteoblasts [30]. Accordingly, Tripti
[31] suggested that canonical Wnt signaling promoted
osteogenesis by directly stimulating the Runx2 gene ex-
pression, which is expressed earlier than the Runx2. The
undifferentiated Wnt expression indicated that CCL3 did
not affect the OB differentiation in the early developmental
stages of bone formation. Future studies should confirm
these effects by using a larger sample size.
We exposed MM-derived OBs to CCL3 in the pres-
ence of neutralizing CCL3 antibodies to confirm the
relevance of this chemokine in the MM-induced OB
impairment. The CCL3 antibody treatment partially
restored the Runx2 and Osx expressions in the OBs of
patients with MM. The OCN levels in the culture super-
natant also increased. Accordingly, CCL3 played a signifi-
cant role in suppressing OB differentiation and function.
Conclusion
The OB inhibition induced by CCL3 is associated with the
Runx2/Osx pathway and the suppression of mineralization
activation and OCN expression. These findings are useful
in developing OB promotion. Using the CCL3 inhibitor
helps control bone destruction with OB/OC coupling in
patients with MBD and improves the patients’ quality of
life if OB inhibition is partly induced by CCL3.
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